Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health provider marketplace matching patients with therapists and psychiatrists accepting insurance; San Francisco-based;
Path Mental Health is a San Francisco-based mental health platform that matches patients with therapists, psychologists, and psychiatrists who accept insurance, addressing the core access barrier in mental healthcare. Path handles the insurance verification, paperwork, and administrative overhead of connecting patients to in-network mental health providers, offering both individual therapy and medication management services. The platform targets the large population of individuals who want to use their health insurance for mental health care but struggle to find providers who are accepting new patients and take their specific insurance plan. Path works with major commercial insurers and provides access to licensed providers via telehealth and in-person sessions depending on location. Founded in 2019, Path raised over $120M from investors including Andreessen Horowitz and Foresite Capital. The company competes with Alma, Headway, and Grow Therapy in the therapist network and patient matching market.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.